This antibody was included in a study aiming to characterize and validate commecially available antibodies raised against myocilin. Epitope mapping was conducted using recombinant myocilin subdomains cloned and expressed in E. coli. As positive control was used endogenously expressed full-length human myocilin secreted by trabecular meshwork (TM) cells.
We evaluated four antibodies (Ab41552, MABN866, MAB3446, sc-137233) for application in Western blotting (denaturing conditions) and ELISA (native protein).
Our data show that MABN866 recognizes epitopes within the amino acid sequence 33-111.
The antibody works very well for WB, and detects E. coli expressed myocilin fragments containing these residues as well as the full-length human protein.
The epitope was confirmed in ELISA, however the antibody is sensitive to the presence of disulfide bonds involving C47 and C61.
For further information see Patterson-Orazem et al., 2018 “Epitope mapping of commercial antibodies that detect myocilin” (www.ncbi.nlm.nih.gov/pubmed/29752947)
On September 4, 2018 Athéna C. Patterson-Orazem, Georgia Institute of Technology wrote:
This antibody was included in a study aiming to characterize and validate commecially available antibodies raised against myocilin. Epitope mapping was conducted using recombinant myocilin subdomains cloned and expressed in E. coli. As positive control was used endogenously expressed full-length human myocilin secreted by trabecular meshwork (TM) cells.
We evaluated four antibodies (Ab41552, MABN866, MAB3446, sc-137233) for application in Western blotting (denaturing conditions) and ELISA (native protein).
Our data show that MABN866 recognizes epitopes within the amino acid sequence 33-111.
The antibody works very well for WB, and detects E. coli expressed myocilin fragments containing these residues as well as the full-length human protein.
The epitope was confirmed in ELISA, however the antibody is sensitive to the presence of disulfide bonds involving C47 and C61.
For further information see Patterson-Orazem et al., 2018 “Epitope mapping of commercial antibodies that detect myocilin” (www.ncbi.nlm.nih.gov/pubmed/29752947)